| [1] |
Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs-mechanisms and therapeutic implications [J]. Nat Rev Endocrinol, 2015, 11(10): 592-605.
|
| [2] |
Roden M. Blocking fatty acids′ mystery tour: a therapy for metabolic syndrome? [J]. Cell Metabol, 2007, 6(2): 89-91.
|
| [3] |
Shi M, Ma L, Fu P. Role of fatty acid binding orotein 4 (FABP4) in kidney disease [J]. Cur Med Chem, 2020, 27(22): 3657-3664.
|
| [4] |
Tanaka M, Furuhashi M, Okazaki Y, et al. Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction [J]. Nephron Clin Pract, 2014, 128(3-4): 345-351.
|
| [5] |
Elmasri H, Karaaslan C, Teper Y, et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells [J]. FASEB J, 2009, 23(11): 3865-3673.
|
| [6] |
Yao F, Li Z, Ehara T, et al. Fatty acid-binding protein 4 mediates apoptosis via endoplasmic reticulum stress in mesangial cells of diabetic nephropathy [J]. Mol Cell Endocrinol, 2015, 411: 232-242.
|
| [7] |
Shi M, Huang R, Guo F, et al. Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against renal ischemia-reperfusion injury [J]. RSC Adv, 2018, 8: 15207-15214.
|
| [8] |
Huang R, Shi M, Guo F, et al. Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against rhabdomyolysis-induced acute kidney injury [J]. Front Pharmacol, 2018, 9: 917.
|
| [9] |
Tan Z, Guo F, Huang Z, et al. Pharmacological and genetic inhibition of fatty acid-binding protein 4 alleviated cisplatin-induced acute kidney injury [J]. J Cell Mol Med, 2019, 23(9): 6260-6270.
|
| [10] |
Shi M, Guo F, Liao D, et al. Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy [J]. Eur J Pharmocol, 2020, 887: 173570.
|
| [11] |
Feng Y, Guo F, Xia Z, et al. Inhibition of fatty acid-binding protein 4 attenuated kidney fibrosis by mediating macrophage-to-myofibroblast transition [J]. Front Immunol, 2020, 11: 566535.
|
| [12] |
Taguchi K, Chen L, Usawachintachit M, et al. Fatty acid-binding protein 4 downregulation drives calcification in the development of kidney stone disease [J]. Kidney Int, 2020, 97(5): 1042-1056.
|
| [13] |
Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome [J]. Clin Chem, 2006, 52(3): 405-413.
|
| [14] |
Hao J, Zhang Y, Yan X, et al. Circulating adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development [J]. Cell Metabol, 2018, 28(5): 689-705.
|
| [15] |
Ebert T, Hopf LM, Wurst U, et al. Circulating adipocyte fatty acid binding protein is increased in chronic and acute renal dysfunction [J]. Nutr Metab Cardiovasc Dis, 2014, 24(9): 1027-1034.
|
| [16] |
Fuseya T, Furuhashi M, Yuda S, et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population [J]. Cardiovasc Diabetol, 2014, 13: 126.
|
| [17] |
Sommer G, Ziegelmeier M, Bachmann A, et al. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD) [J]. Clin Endocrinol, 2008, 69(6): 901-905.
|
| [18] |
Toruner F, Altinova A, Akturk M, et al. The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes [J]. Diabetes Res Clin Pract, 2011, 91(2): 203-207.
|
| [19] |
Lee C, Cheung CYY, Woo YC, et al. Prospective associations of circulating adipocyte fatty acid-binding protein levels with risks of renal outcomes and mortality in type 2 diabetes [J]. Diabetologia, 2019, 62(1): 169-177.
|
| [20] |
Li B, Yang H, Zhang W, et al. Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus [J]. PLoS One, 2018, 13(2): e0192347.
|
| [21] |
Okazaki Y, Furuhashi M, Tanaka M, et al. Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction [J]. PLoS One, 2014, 9(12): e115429.
|
| [22] |
Obajdin J, Cotter M, Snelling S, et al. Fatty-acid binding protein 4 (FABP4) as a potential preclinical biomarker of drug-induced kidney injury [J]. Toxicol Sci, 2018, 166(2): 441-450.
|
| [23] |
Furuhashi M, Ishimura S, Ota H, et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease [J]. PLoS One, 2011, 6(11): e27356.
|
| [24] |
Bao Y, Lu Z, Zhou M, et al. Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women [J]. PLoS One, 2011, 6(4): e19115.
|
| [25] |
Chen Y, Hsu B, Lee C, et al. Serum adipocyte fatty acid-binding protein level is associated with arterial stiffness quantified with cardio-ankle vascular index in kidney transplant patients [J]. Clin Exp Nephrol, 2018, 22(1): 188-195.
|
| [26] |
Furuhashi M, Tuncman G, Gorgun C, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 [J]. Nature, 2007, 447(7147): 959-965.
|
| [27] |
Qiao Y, Liu L, Yin L, et al. FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism [J]. Cell Death Dis, 2019, 10(6): 382.
|